Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The sodium‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis
Julia Moellmann, Pascal Alexander Mann, Ben A. Kappel, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 11, pp. 2263-2272
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Circulation (2022) Vol. 146, Iss. 18, pp. 1383-1405
Open Access | Times Cited: 256
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
Faı̈ez Zannad, João Pedro Ferreira, Javed Butler, et al.
European Heart Journal (2022) Vol. 43, Iss. 48, pp. 4991-5002
Open Access | Times Cited: 136
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Milton Packer
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 443-462
Open Access | Times Cited: 96
Ketones and the Heart: Metabolic Principles and Therapeutic Implications
Timothy Matsuura, Patrycja Puchalska, Peter A. Crawford, et al.
Circulation Research (2023) Vol. 132, Iss. 7, pp. 882-898
Open Access | Times Cited: 72
Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
Rosalba La Grotta, Chiara Frigé, Giulia Matacchione, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12325-12325
Open Access | Times Cited: 39
Acquired cardiovascular disease in adults with congenital heart disease
Margarita Brida, Salvatore De Rosa, Antoine Legendre, et al.
European Heart Journal (2023) Vol. 44, Iss. 43, pp. 4533-4548
Open Access | Times Cited: 31
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
B K Chen, Jing Guo, Ye Hongmei, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 5
Open Access | Times Cited: 9
Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention
Yi Zhu, Jiali Zhang, Xue-jiao Yan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 38
Research progress on post-translational modification of proteins and cardiovascular diseases
Xueli Cheng, Kai Wang, Yan Zhao, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 19
SGLT2 inhibitors: how do they affect the cardiac cells
Betül Rabia Erdoğan, Ebru Arioglu‐Inan
Molecular and Cellular Biochemistry (2024)
Closed Access | Times Cited: 6
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis
Jun-Pei Hu, Jianhui Teng, Shan Hui, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e29486-e29486
Open Access | Times Cited: 5
The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation
Bo Pang, Lulu Zhang, Bin Li, et al.
Physiology & Behavior (2023) Vol. 263, pp. 114134-114134
Closed Access | Times Cited: 12
New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling
Yang Chen, Daoquan Peng
International Immunopharmacology (2023) Vol. 118, pp. 110072-110072
Open Access | Times Cited: 12
Serinc2 antagonizes pressure overload-induced cardiac hypertrophy via regulating the amino acid/mTORC1 signaling pathway
Shuai Mao, Manqi Yang, Huimin Liu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 3, pp. 167650-167650
Closed Access
A comprehensive review of the efficacy and safety of ertugliflozin
Bo Xu, Yilin Liu, Tianqiao Zhang, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025)
Closed Access
Improvement of Global Longitudinal Strain and Myocardial Work in Type 2 Diabetes Patients on Sodium–Glucose Cotransporter 2 Inhibitors Therapy
Vincenzo Russo, Marco Malvezzi Caracciolo D’Aquino, Alfredo Caturano, et al.
Journal of Cardiovascular Pharmacology (2023)
Closed Access | Times Cited: 10
Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity
Yuansheng Wu
Experimental Biology and Medicine (2023) Vol. 248, Iss. 18, pp. 1556-1565
Open Access | Times Cited: 10
Implications of endoplasmic reticulum stress and autophagy in aging and cardiovascular diseases
Chenguang Ma, Yang Liu, Zhiling Fu
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
2,8-Dihydroxyadenine-induced nephropathy causes hexosylceramide accumulation with increased mTOR signaling, reduced levels of protective SirT3 expression and impaired renal mitochondrial function
Julia Moellmann, Katja Krueger, Dickson W.L. Wong, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2023) Vol. 1870, Iss. 1, pp. 166825-166825
Open Access | Times Cited: 7
SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis
Yutaro Hirashima, Toshiaki Nakano, Kumiko Torisu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
Klaudia Kowalska, Piotr Wilczopolski, Dominika Buławska, et al.
Antioxidants (2022) Vol. 11, Iss. 12, pp. 2500-2500
Open Access | Times Cited: 8
Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later
Wenqi Tao, Xiaoyu Yang, Qing Zhang, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 4
Examining the Impact of Ertugliflozin on Cardiovascular Outcomes in Patients with Diabetes and Metabolic Syndrome: A Systematic Review of Clinical Trials
S. Pescariu, Ahmed Elagez, Balaji Nallapati, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 929-929
Open Access | Times Cited: 1
SGLT2 inhibitors in heart failure: insights from plasma proteomics
Clemens Gutmann, Thomas A. Zelniker, Manuel Mayr
European Heart Journal (2022) Vol. 43, Iss. 48, pp. 5003-5005
Closed Access | Times Cited: 6
The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins
П Н Боднар, M Mazurkiewicz, Tomasz Chwalba, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2236-2236
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top